These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33209684)

  • 1. Angiogenesis related gene expression significantly associated with the prognostic role of an urothelial bladder carcinoma.
    Wang J; Guo M; Zhou X; Ding Z; Chen X; Jiao Y; Ying W; Wu S; Zhang X; Geng N
    Transl Androl Urol; 2020 Oct; 9(5):2200-2210. PubMed ID: 33209684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of prognostic oncogene filaggrin (
    Chen L; Huang X; Xiong L; Chen W; An L; Wang H; Hong Y; Wang H
    Transl Androl Urol; 2022 Oct; 11(10):1419-1432. PubMed ID: 36386263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis and immune infiltration analysis of endoplasmic reticulum stress-related genes in bladder urothelial carcinoma.
    Wang Y; Zhu H; Wang X
    Front Genet; 2022; 13():965100. PubMed ID: 36186448
    [No Abstract]   [Full Text] [Related]  

  • 5. PGM1 and ENO1 Promote the Malignant Progression of Bladder Cancer via Comprehensive Analysis of the m6A Signature and Tumor Immune Infiltration.
    Zhao J; Huang S; Tan D; Yang K; Chen M; Jia X; Mao X
    J Oncol; 2022; 2022():8581805. PubMed ID: 35251177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of the Prognostic Stemness Biomarkers in Bladder Cancer Bone Metastasis.
    Kang Y; Zhu X; Wang X; Liao S; Jin M; Zhang L; Wu X; Zhao T; Zhang J; Lv J; Zhu D
    Front Oncol; 2021; 11():641184. PubMed ID: 33816287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration.
    Zhou Z; Zhou Y; Zhou X; Huang Y; Cui Y; Zhang Y
    J Oncol; 2022; 2022():1146186. PubMed ID: 35799606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of
    Lin B; Zhang T; Ye X; Yang H
    Oncol Lett; 2020 Sep; 20(3):2840-2854. PubMed ID: 32782602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Pyroptosis-Related Gene Signatures Identified as the Prognostic Biomarkers for Bladder Carcinoma.
    You J; Li H; Wei Y; Fan P; Zhao Y; Yi C; Guo Q; Yang X
    Front Oncol; 2022; 12():881860. PubMed ID: 35847844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival.
    Chen Z; Liu G; Hossain A; Danilova IG; Bolkov MA; Liu G; Tuzankina IA; Tan W
    Hereditas; 2019; 156():24. PubMed ID: 31333338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening
    Yang T; Chi Z; Liu G; Hong X; Cao S; Cheng K; Zhang Y
    Front Genet; 2023; 14():1107625. PubMed ID: 37051591
    [No Abstract]   [Full Text] [Related]  

  • 13. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
    Mi Y; Wang X
    J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment.
    Chen J; Lv B; Zhan Y; Zhu K; Zhang R; Chen B; Jin Y; Li Y; Zheng J; Lin C
    Front Oncol; 2022; 12():724261. PubMed ID: 35237505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Significance of Proteasome 26S Subunit, Non-ATPase (PSMD) Genes for Bladder Urothelial Carcinoma Patients.
    Salah Fararjeh A; Al-Khader A; Al-Saleem M; Abu Qauod R
    Cancer Inform; 2021; 20():11769351211067692. PubMed ID: 34992336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
    Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma.
    Lin P; Wen DY; Chen L; Li X; Li SH; Yan HB; He RQ; Chen G; He Y; Yang H
    Eur Radiol; 2020 Jan; 30(1):547-557. PubMed ID: 31396730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma.
    Zhang F; Liang J; Feng D; Liu S; Wu J; Tang Y; Liu Z; Lu Y; Wang X; Wei X
    Front Cell Dev Biol; 2022; 10():814735. PubMed ID: 35281080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.